AROMUC 5AC
Alternative Names: ARO-MUC5ACLatest Information Update: 27 Dec 2024
Price :
$50 *
At a glance
- Originator Arrowhead Pharmaceuticals
- Class Antiasthmatics; Small interfering RNA
- Mechanism of Action Mucin 5AC expression inhibitors; RNA interference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I/II Asthma; Chronic obstructive pulmonary disease
- Phase I Obstructive airway disorders
Most Recent Events
- 23 Dec 2024 Arrowhead Pharmaceuticals terminates phase-I/IIa trial in Asthma and Chronic obstructive pulmonary disease (Treatment-experienced) in Australia, South Korea, New Zealand, Poland, Spain, Thailand and United Kingdom due to business reason (NCT05292950)
- 20 Jun 2023 Phase-I clinical trials in Obstructive airway disorders (Inhalation) (Arrowhead Pharma pipeline, June 2023)
- 07 Jun 2023 Phase-I/II clinical trials in Asthma (Treatment-experienced) in Spain (Inhalation) (EudraCT2022-003467-21)